Tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib have markedly improved outcomes of patients with chronic myeloid leukemia, the majority of which is caused by the classical oncogenic fusion gene BCR-ABL [12, 13]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.